BACKGROUND: The purpose of this study is to evaluate the response to and benefit of first-line metastatic treatment (including re-exposure to trastuzumab) for patients relapsing after exposure to adjuvant trastuzumab (AT). PATIENTS AND METHODS: All HER2-positive breast cancer cases relapsing after exposure to AT at our institutions were identified. Clinico-pathologic details, pattern of relapse, and treatment in the metastatic setting were documented. Response to treatment and outcome were assessed. RESULTS: Twenty-nine relapses were recorded. The median time to relapse was 18.4 months from diagnosis, and 8.7 months from AT initiation. At a median time of observation of 9.9 months, 18 patients had progressed on first-line therapy. The median time-to-progression (TTP) was 8.6 months. Fifteen patients received trastuzumab as first-line treatment, with no statistical difference in TTP between this group and those not re-exposed to trastuzumab. TTP was not statistically different between those relapsing on or after AT. Overall survival was longer for those who relapsed after completion of 1 year of AT as well as those who received further trastuzumab at relapse; however, this did not reach statistical significance. CONCLUSION: Overall survival was longer in patients who relapse after completion of AT and who received further trastuzumab at progression.
BACKGROUND: The purpose of this study is to evaluate the response to and benefit of first-line metastatic treatment (including re-exposure to trastuzumab) for patients relapsing after exposure to adjuvant trastuzumab (AT). PATIENTS AND METHODS: All HER2-positive breast cancer cases relapsing after exposure to AT at our institutions were identified. Clinico-pathologic details, pattern of relapse, and treatment in the metastatic setting were documented. Response to treatment and outcome were assessed. RESULTS: Twenty-nine relapses were recorded. The median time to relapse was 18.4 months from diagnosis, and 8.7 months from AT initiation. At a median time of observation of 9.9 months, 18 patients had progressed on first-line therapy. The median time-to-progression (TTP) was 8.6 months. Fifteen patients received trastuzumab as first-line treatment, with no statistical difference in TTP between this group and those not re-exposed to trastuzumab. TTP was not statistically different between those relapsing on or after AT. Overall survival was longer for those who relapsed after completion of 1 year of AT as well as those who received further trastuzumab at relapse; however, this did not reach statistical significance. CONCLUSION: Overall survival was longer in patients who relapse after completion of AT and who received further trastuzumab at progression.
Authors: Hánah N Rier; Mark-David Levin; Joost van Rosmalen; Monique M E M Bos; Jan C Drooger; Paul de Jong; Johanneke E A Portielje; Elisabeth M P Elsten; Albert-Jan Ten Tije; Stefan Sleijfer; Agnes Jager Journal: Oncologist Date: 2017-05-22
Authors: Nakul Saxena; Mikael Hartman; Nirmala Bhoo-Pathy; Jennifer N W Lim; Tar-Ching Aw; Philip Iau; Nur Aishah Taib; Soo-Chin Lee; Cheng-Har Yip; Helena M Verkooijen Journal: World J Surg Date: 2012-12 Impact factor: 3.352
Authors: Benjamin Daniels; Belinda E Kiely; Nehmat Houssami; Sarah J Lord; Timothy Dobbins; Christine Y Lu; Robyn L Ward; Sallie-Anne Pearson Journal: Br J Cancer Date: 2017-11-14 Impact factor: 7.640
Authors: Gedmante Radziuviene; Allan Rasmusson; Renaldas Augulis; Daiva Lesciute-Krilaviciene; Aida Laurinaviciene; Eduard Clim; Arvydas Laurinavicius Journal: Biomed Res Int Date: 2017-05-28 Impact factor: 3.411
Authors: Benjamin Daniels; Sarah J Lord; Belinda E Kiely; Nehmat Houssami; Philip Haywood; Christine Y Lu; Robyn L Ward; Sallie-Anne Pearson Journal: BMJ Open Date: 2017-01-24 Impact factor: 2.692